These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
405 related articles for article (PubMed ID: 12703998)
41. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W; Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325 [TBL] [Abstract][Full Text] [Related]
42. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas. Voulgarelis M; Giannouli S; Anagnostou D; Tzioufas AG Rheumatology (Oxford); 2004 Aug; 43(8):1050-3. PubMed ID: 15187246 [TBL] [Abstract][Full Text] [Related]
43. Stage I and II non-Hodgkin's lymphoma: results of combined of THP-COP chemotherapy and radiotherapy. Ohga S; Nakamura K; Shioyama Y; Sasaki T; Urashima Y; Terashima H; Honda H Radiat Med; 2005 May; 23(3):156-61. PubMed ID: 15940061 [TBL] [Abstract][Full Text] [Related]
44. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Mead GM; Bleehen NM; Gregor A; Bullimore J; Shirley D; Rampling RP; Trevor J; Glaser MG; Lantos P; Ironside JW; Moss TH; Brada M; Whaley JB; Stenning SP Cancer; 2000 Sep; 89(6):1359-70. PubMed ID: 11002232 [TBL] [Abstract][Full Text] [Related]
45. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma]. Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560 [TBL] [Abstract][Full Text] [Related]
46. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. Feugier P; Van Hoof A; Sebban C; Solal-Celigny P; Bouabdallah R; Fermé C; Christian B; Lepage E; Tilly H; Morschhauser F; Gaulard P; Salles G; Bosly A; Gisselbrecht C; Reyes F; Coiffier B J Clin Oncol; 2005 Jun; 23(18):4117-26. PubMed ID: 15867204 [TBL] [Abstract][Full Text] [Related]
47. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467 [TBL] [Abstract][Full Text] [Related]
48. [Evaluation of efficacy of treatment for 30 children with neuroblastoma]. Sun XF; Liu DG; Su YS; Lin TY; Chen XQ; He YJ Ai Zheng; 2003 Dec; 22(12):1343-5. PubMed ID: 14693065 [TBL] [Abstract][Full Text] [Related]
49. Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma. Daum S; Ullrich R; Heise W; Dederke B; Foss HD; Stein H; Thiel E; Zeitz M; Riecken EO J Clin Oncol; 2003 Jul; 21(14):2740-6. PubMed ID: 12860953 [TBL] [Abstract][Full Text] [Related]
50. Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center. Mora J; Filippa DA; Qin J; Wollner N Cancer; 2003 Sep; 98(6):1283-91. PubMed ID: 12973853 [TBL] [Abstract][Full Text] [Related]
51. Localized stage I-IE aggressive non-Hodgkin's lymphoma (NHL): results of prospective study with multimodality therapeutic approach. De Sanctis V; Martelli M; Anticoli AP; Caronna R; Chirletti P; Giovannini M; Santarelli M; Enrici RM; Mandelli F Anticancer Res; 2001; 21(6A):4169-72. PubMed ID: 11911313 [TBL] [Abstract][Full Text] [Related]
52. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A; J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521 [TBL] [Abstract][Full Text] [Related]
53. [Comparing CHOP, CHOP+HD-MTX,and BFM-90 regimens in the survival rate of children and adolescents with B cell non-Hodgkin's lymphoma]. Sun XF; Su YS; Liu DG; Jiang WQ; He YJ; Lin TY; Huang HQ; Zhang L; Xia ZJ; Li YH; Zhou ZM; Chen XQ; Xia Y; Zhen ZJ; Guan ZZ Ai Zheng; 2004 Aug; 23(8):933-8. PubMed ID: 15301718 [TBL] [Abstract][Full Text] [Related]
54. Adapted CHOP plus rituximab in non-Hodgkin's lymphoma in patients over 80 years old. Italiano A; Jardin F; Peyrade F; Saudes L; Tilly H; Thyss A Haematologica; 2005 Sep; 90(9):1281-3. PubMed ID: 16154857 [TBL] [Abstract][Full Text] [Related]
55. Plasma glutathione S-Transferase P1-1 as a prognostic factor in patients with advanced non-Hodgkin's lymphoma (stages III and IV). Katahira T; Takayama T; Miyanishi K; Hayashi T; Ikeda T; Takahashi Y; Takimoto R; Matsunaga T; Kato J; Niitsu Y Clin Cancer Res; 2004 Dec; 10(23):7934-40. PubMed ID: 15585627 [TBL] [Abstract][Full Text] [Related]
56. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. Czuczman MS; Weaver R; Alkuzweny B; Berlfein J; Grillo-López AJ J Clin Oncol; 2004 Dec; 22(23):4711-6. PubMed ID: 15483015 [TBL] [Abstract][Full Text] [Related]
57. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Voulgarelis M; Giannouli S; Tzioufas AG; Moutsopoulos HM Ann Rheum Dis; 2006 Aug; 65(8):1033-7. PubMed ID: 16322082 [TBL] [Abstract][Full Text] [Related]
58. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma]. Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571 [TBL] [Abstract][Full Text] [Related]
59. [Treatment and prognostic factors of stage I and II non-Hodgkin's lymphoma]. Mineta M; Saitoh Y; Hayasaka K; Takashio T; Kikuchi Y; Aburano T Hokkaido Igaku Zasshi; 1994 Mar; 69(2):347-53. PubMed ID: 8157259 [TBL] [Abstract][Full Text] [Related]
60. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease. Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]